Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging

• Status: Not yet recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is based on the Flutemetamol-PET senile plaque imaging to investigate the peripheral blood biochemical and brain MRI imaging biomarkers and to research completely independent intellectual property rights neuropsychological test tool for the MCI due to AD. At the same time, the investigators will study the efficacy and safety of early treatment of MCI due to AD by Huperzine A in 52 weeks.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Mental Health Center
• Treatments: Huperzine A

Criteria

Inclusion Criteria:

• memory complaint, preferably corroborated by a spouse or relative.

• objective memory impairment.

• normal general cognitive function.

• intact activities of daily living.

• absence of dementia.

• the positive of brain senile plaque.

Exclusion Criteria:

• more than two lacuna ischemia (of diameter < 1 cm) as revealed by MRI fluid-attenuated inversion recovery (FLAIR) sequence.

• other type of dementia except AD